Machado, TiagoDuarte, Gonçalo SilvaGonçalves, Nilza C.Ferreira, Joaquim J.Costa, João2019-10-232019-10-232019-10Lancet Oncol. 2019 Oct;20(10):e5531470-2045http://hdl.handle.net/10451/39924Copyright © 2019 Elsevier B.V. or its licensors or contributors.In The Lancet Oncology , Joseph Del Paggio and Ian Tannock report on a retrospective analysis of the fragility indices of phase 3 trials used by the US Food and Drug Administration (FDA) to approve anticancer drugs. 1 The authors conclude that “many phase 3 randomised controlled trials supporting FDA-approved anticancer drugs have a low fragility index, challenging confidence for concluding their superiority over control treatments.” Although this interpretation is interesting, we would like to draw attention to several points.engjournal article10.1016/S1470-2045(19)30581-9.